Combined with the published data of the negative side effects of anti-COX2 treatments, and the importance of inhibiting a pro-tumor immune tolerance, these data suggest that the treatment of breast cancer should be focused on targeting PGE2-specific receptors. The gene discussed is PTGS2; the disease is breast cancer.